| Drug Name | (Tecentriq®( Atezolizumab |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Patient Card
Direct Healthcare Professional Communication DHPC
Healthcare provider guide
Safety communication
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Safety information about risk of Immune-related adverse reactions A New Important Identified Risk: Nephritis |
| Patient card |
|
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|